Base Year
Historical Year
Forecast Year
The global dyspnea market size was valued at USD 6.5 billion in 2023, driven by increasing prevalence of respiratory disorders across the 8 major markets. The market is expected to grow at a CAGR of 6.9% during the forecast period of 2024-2032, with the values likely to rise from USD 6.9 billion in 2024 to USD 11.8 billion by 2032.
Dyspnea involves breathlessness or breathing discomfort characterized by distinct sensations that vary in intensity. It may occur due to heavy physical exertion, or as a side effect of asthma, cardiac ischemia, pneumonia, and congestive heart failure, among others. Dyspnea has become more common after COVID-19, as the virus primarily attacked the lungs of patients. As per a study conducted in 76 patients, clinical meaningful dyspnea affected 49% of the patients at 3 months, while 24% of the patients experienced the symptoms getting worse between 3-12 after COVID-19 exposure.
The dyspnea market growth is driven by the advent of targeted therapies modes, aimed to offer effective treatment. The market is experiencing a surge in research and development activities for the development of new drugs and therapies. The increasing prevalence of respiratory disorders such as asthma, pneumonia, myocardial ischemia, and other respiratory disorders globally is a major factor contributing to the market share. The market is further expected to be driven by the rising prevalence of indoor as well as outdoor pollution. The rising expenditure on the development of healthcare infrastructure is another major factor bolstering the market value.
FDA Approvals to Develop Effective Treatment Alternative to Patients
The market is expected to experience significant growth driven by the increased prevalence of respiratory disorders such as asthma. To meet the dyspnea market demand, there has been a surge in new drug developments and their FDA approvals. For instance, in January 2023, the U.S. FDA approved Airsupra, an inhalational aerosol to treat asthma in adults (18 or older). Administered as a combination of albuterol and budesonide, it is the foremost combination of an inhaled corticosteroid and short-acting beta-agonist. The increasing incidence of FDA approvals is expected to fill a crucial gap of unmet needs in asthma treatment. In addition, increasing drug approvals are also expected to spark competition among key players, bolstering the market growth in the forecast period.
Surge in Investments to Drive Market Growth
The increased initiatives from the government to spread awareness about respiratory disorders and to get diagnosed in time for appropriate treatment are some of the significant dyspnea market trends. Moreover, an increasing number of funding activities to fetch treatments for asthma and other respiratory are collectively influencing market growth. For instance, in October 2023, San Francisco and London-based Aiolos Bio (a new startup with an asthma drug in clinical trials) declared that it raised USD 245 million in Series A funding. Such fundings support the development of drugs for clinical treatment, leading to expansion of the market.
Market Breakup by Treatment Type
Market Breakup by Drug Class
Market Breakup by Route of Administration
Market Breakup by End User
Market Breakup by Region
North America is leading the regional market, driven by the presence of advanced treatments and the availability of distribution channels to access appropriate drugs for treatment. The presence of a robust healthcare system is a major factor attributing to the growth of the region. In November 2023, Dupixent® (dupilumab ), Sanofi’s investigational drug for treating COPD showed positive results in the Phase 3 BOREAS trial. The drug reduced COPD exacerbations by 34%. As a part of the results, it was also revealed that the drug offered improvement in lung function by 12 weeks, and it was sustained at 52 weeks. The existence of prominent healthcare companies attribute to the dyspnea market share in the region.
Europe, having several research and academic institutions holds a significant market share. In addition, a huge geriatric population base is expected to increase the demand for dyspnea treatment in the forecast period.
Asia Pacific is poised to witness significant growth, owing to rising investments in improving the medical infrastructure. There has been substantial development and prevalence for alternative therapies to treat the condition in patients. The amalgamation of traditional medicine with novel techniques is anticipated to drive the dyspnea market size in the region.
In July 2023, Lupin Limited , revealed that its Australian subsidiary, Generic Health Pty Ltd, received approval for Tiotropium 18 micrograms powder for inhalation from Therapeutic Goods Administration (TGA). The approved drug can be used in combination with Lupin Haler and is indicated treating long-term bronchospasm along with dyspnea associated with chronic obstructive pulmonary disease (COPD). It has also been found effective in preventing COPD exacerbations. The surge in drug approvals from key regulatory authorities has been a major market trend, expected to boost the market size in the forecast period.
The key features of the dyspnea market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Please note that this only represents a partial list of companies, and the complete list has been provided in the report.
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Treatment Type |
|
| Breakup by Drug Class |
|
| Breakup by Route of Administration |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
The market attained a value of about USD 6.5 billion in 2023 driven by the rising prevalence of respiratory diseases across the 8 major markets.
The market is anticipated to grow at a CAGR of 6.9% during the forecast period, likely to reach a market value of USD 11.8 billion by 2032.
The increasing prevalence of indoor and outdoor pollutants, increased initiatives by the government to spread awareness among people regarding dyspnea and its treatments, increased prevalence of COPD, and increased FDA approvals are major factors contributing to the market demand.
The increasing number of clinical trials examining the efficacy of drugs, leading to growth in drug approvals from essential regulatory bodies is a major market trend. In July 2023, Lupin's Tiotropium 18 micrograms powder received approval from Therapeutic Goods Administration (TGA) to treat long-term bronchospasm along with dyspnea associated with chronic obstructive pulmonary disease (COPD).
The major regions of the market include United States, EU-4, the United Kingdom, Japan, and China. EU-4 is further divided into Germany, France, Italy, and Spain.
Types of treatments in the market include supplemental oxygen therapy and relaxation therapy.
Types of drug classes used for dyspnea treatment are antianxiety, antibiotics, anticholinergic agents, corticosteroids, and others.
The routes of administration include oral and inhalation, among others.
End users in the market include hospitals, specialty clinics, homecare, ambulatory services, and others.
Key players involved in the market are Bausch Health, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd, Ligand Pharmaceuticals Incorporated, Amneal Pharmaceuticals LLC, Jazz Pharmaceuticals, Inc., Mylan N.V., Lupin, Pfizer Inc., Novartis AG, Boehringer Ingelheim International GmbH, Sun Pharmaceutical Industries Ltd, Aurobindo Pharma, Nephron Pharmaceuticals Corporation, and Zydus Cadila.
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Subscribe to our Newsletter
By subscribing you agree to with our privacy policy and provide
consent to
receive
updates
from our company.
Australia
63 Fiona Drive, Tamworth, NSW
+61 448 06 17 27
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63 287899028, +63 967 048 3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84865399124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61 448 06 17 27
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63 287899028, +63 967 048 3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84865399124
Share